Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Phase III study of sulopenem in cUTI does not meet primary endpoint

June 2, 2020

CTI enrolling patients in phase III PREVENT trial of pacritinib in severe COVID-19

June 2, 2020

FDA clears Opko to begin phase II trial of Rayaldee for mild to moderate COVID-19

June 2, 2020

Gilead reports phase III data on remdesivir in moderate COVID-19 pneumonia

June 2, 2020

Novus reports topline phase IIa data on OP-0201 in acute otitis media

June 2, 2020

SAB Biotherapeutics plans to initiate clinical testing of potential COVID-19 therapeutic

May 29, 2020

resTORbio initiates study of RTB-101 as antiviral prophylaxis to reduce severity of COVID-19

May 29, 2020

FDA agrees to phase II study of OP-101 in severe COVID-19

May 29, 2020

NantKwest and ImmunityBio agreement to support development COVID-19 therapeutics and vaccines

May 29, 2020

Vir Biotechnology initiates first-in-human study of VIR-3434

May 29, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 16, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...